These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 8743039)

  • 1. Cardiovascular structural alterations in hypertension: effect of treatment.
    Agabiti-Rosei E; Muiesan ML; Rizzoni D
    Clin Exp Hypertens; 1996; 18(3-4):513-22. PubMed ID: 8743039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of antihypertensive agents on the left ventricle: clinical implications.
    Díez J; González A; López B; Ravassa S; Fortuño MA
    Am J Cardiovasc Drugs; 2001; 1(4):263-79. PubMed ID: 14728026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM; Schmieder RE
    Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of left ventricular hypertrophy in human hypertension.
    Kahan T
    J Hypertens Suppl; 1998 Sep; 16(7):S23-9. PubMed ID: 9855028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early target organ damage and its reversibility: the heart.
    Rosei EA; Muiesan ML
    Clin Exp Hypertens; 2004; 26(7-8):673-87. PubMed ID: 15702622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the cardiac effects of antihypertensive agents.
    Agabiti-Rosei E
    J Cardiovasc Pharmacol; 1994; 23 Suppl 5():S42-8. PubMed ID: 7609505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Goals of antihypertensive therapy.
    McVeigh GE; Flack J; Grimm R
    Drugs; 1995 Feb; 49(2):161-75. PubMed ID: 7729325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE-inhibitor perindopril.
    Sihm I; Schroeder AP; Aalkjaer C; Holm M; Mørn B; Mulvany M; Thygesen K; Lederballe O
    Blood Press; 1995 Jul; 4(4):241-8. PubMed ID: 7496564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antihypertensive treatment and left ventricular hypertrophy].
    Agabiti-Rosei E; Muiesan ML; Rizzoni D
    Ann Ital Med Int; 1993 Oct; 8 Suppl():97S-103S. PubMed ID: 8117529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural cardiovascular changes in essential hypertension. Studies on the effect of antihypertensive therapy.
    Dahlöf B
    Blood Press Suppl; 1992; 6():1-75. PubMed ID: 1345261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
    Thomas GN; Chan P; Tomlinson B
    Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies.
    Schmieder RE; Martus P; Klingbeil A
    JAMA; 1996 May; 275(19):1507-13. PubMed ID: 8622227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiology and clinical aspects of hypertensive hypertrophy.
    Vogt M; Motz WH; Schwartzkopf B; Strauer BE
    Eur Heart J; 1993 Jul; 14 Suppl D():2-7. PubMed ID: 8103741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of left ventricular hypertrophy: are there preferred drugs?
    Diamond JA; Phillips RA
    Curr Hypertens Rep; 2003 Oct; 5(5):368-71. PubMed ID: 12948428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regression of small resistance artery structural alterations in hypertension by appropriate antihypertensive treatment.
    Agabiti-Rosei E; Rizzoni D
    Curr Hypertens Rep; 2010 Apr; 12(2):80-5. PubMed ID: 20424941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy.
    Rizzoni D; Muiesan ML; Porteri E; Castellano M; Zulli R; Bettoni G; Salvetti M; Monteduro C; Agabiti-Rosei E
    J Hypertens; 1997 Feb; 15(2):197-204. PubMed ID: 9469796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left Ventricular Hypertrophy in Hypertensive Athletes can be Reduced by Antihypertensive Medication Despite Continuing Intense Aerobic Exercise.
    Ketelhut S; Franz IW; Ketelhut RG
    High Blood Press Cardiovasc Prev; 2018 Dec; 25(4):385-390. PubMed ID: 30341642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of therapeutic studies on regression of left ventricular hypertrophy.
    Schmieder RE; Schlaich MP
    Adv Exp Med Biol; 1997; 432():191-8. PubMed ID: 9433526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.